Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ESLA

Estrella Immunopharma Inc

Apr 29 • 04:00PM ET

1.47

-0.06 -3.92 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: MRNA NVAX BNTX PFE JNJ REGN GILD VRTX AZN-D LLY

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	60.56%	Shs Outstand	37.97M	Perf Week	-18.33%
Market Cap	62.72M	Forward P/E	-	EPS next Y	-	Insider Trans	0.01%	Shs Float	16.83M	Perf Month	42.72%
Enterprise Value	61.34M	PEG	-	EPS next Q	-	Inst Own	2.46%	Short Float	1.58%	Perf Quarter	38.68%
Income	-13.06M	P/S	-	EPS this Y	-	Inst Trans	1.28%	Short Ratio	1.31	Perf Half Y	-35.53%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-413.55%	Short Interest	0.27M	Perf YTD	-5.77%
Book/sh	-0.27	P/C	45.45	EPS next 5Y	-	ROE	-314.60%	52W High	3.15 -53.33%	Perf Year	34.25%
Cash/sh	0.03	P/FCF	-	EPS past 3/5Y	-27.10% -70.08%	ROIC	-	52W Low	0.78 88.46%	Perf 3Y	-86.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.61% 14.27%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-46.67%	Oper. Margin	-	ATR (14)	0.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.90	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.12	EPS Q/Q	44.14%	SMA20	-10.64%	Beta	0.87	Target Price	12.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	10.09%	Rel Volume	0.11	Prev Close	1.53
Employees	-	LT Debt/Eq	-	Earnings	Feb 25	SMA200	5.89%	Avg Volume	202.96K	Price	1.47
IPO	Sep 14, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	22.22% -	Trades		Volume	22,603	Change	-3.92%

Mar-23-26 08:00AM	Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research (Business Wire)
Feb-09-26 07:00AM	Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT & CIBMTR (Business Wire)
Feb-03-26 08:00AM	Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT & CIBMTR (Business Wire) +7.34%
Jan-05-26 08:30AM	Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (Business Wire)
Dec-04-25 08:00AM	Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation (Business Wire) +12.21%
12:13PM	Loading…
Nov-04-25 12:13PM	Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either? (Barchart) -24.92%
Nov-03-25 08:00AM	Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients (Business Wire) +26.03%
Oct-06-25 08:00AM	Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements (Business Wire) +6.87%
Jun-05-25 08:00AM	Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma (Business Wire) +7.07%
Jun-03-25 08:00AM	Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing (Business Wire) -14.00%
May-29-25 11:15PM	Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial (Insider Monkey) +5.15%
08:01AM	Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkins Lymphomas (Business Wire)
Mar-05-25 08:00AM	Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners (Business Wire)
Feb-22-25 08:55AM	Estrella Immunopharma completes first dose cohort in STARLIGHT trial (TipRanks)
Feb-21-25 08:30AM	Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort (Business Wire)
04:46PM	Loading…
Feb-19-25 04:46PM	Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital (Business Wire) +8.76%
Sep-27-24 12:00PM	Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells (Business Wire) +22.69%
Aug-14-24 12:00PM	Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member (Business Wire)
Aug-02-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -18.08%
May-20-24 10:52AM	ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024 (InvestorPlace)
Sep-29-23 10:34AM	TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination (PR Newswire) -6.22%
Sep-18-23 05:00PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire) +34.29% -17.25%
Aug-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-12-23 07:00AM	TradeUP Acquisition Corp. Announces Meeting Date for Stockholders to Approve the Business Combination with Estrella Biopharma, Inc. and Liquidation of Investments Held in the Trust Account into Cash (PR Newswire)

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xu Jiandong	Chief Financial Officer	Oct 07 '25	Buy	1.33	1,000	1,330	265,488	Apr 29 09:36 PM
Xu Jiandong	Chief Financial Officer	Sep 22 '25	Buy	1.16	1,000	1,160	16,700	Apr 29 09:36 PM
Xu Jiandong	Chief Financial Officer	Sep 11 '25	Buy	1.04	100	104	264,588	Apr 29 09:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ESLA

Estrella Immunopharma Inc

Upgrade your Finviz experience